Inogen (INGN) Earnings Date & Reports

Key Takeaways

• Inogen is scheduled to report third-quarter 2026 results after the market close on Thursday, November 5, 2026.
• Wall Street consensus calls for revenue of roughly $92.2 million, nearly flat with the $92.4 million reported in the prior-year quarter.
• Analysts expect a loss of about $0.11 per share, a narrower shortfall than the comparable period a year earlier.
• Management has guided third-quarter revenue to be approximately in line with the third quarter of 2025, citing a U.S. sales channel mix shift.
• International sales have posted double-digit growth for 10 consecutive quarters, helping offset ongoing softness in U.S. direct-to-consumer and rental channels.

Earnings Context and Why It Matters

Inogen, Inc. (Nasdaq: INGN) is a medical technology company that develops portable oxygen concentrators (POCs) and other respiratory products for the homecare setting. Its third-quarter report lands at a pivotal moment in the company's transition, as patients in the U.S. long-term oxygen therapy market increasingly begin treatment on POCs rather than oxygen tanks. This shift is reshaping the company's revenue mix, pressuring direct-to-consumer and rental sales while boosting its business-to-business channel. Investors are watching closely to see whether international momentum and new product traction can carry the top line while the company works toward sustained profitability.

Earnings Expectations

Consensus estimates point to third-quarter revenue of approximately $92.2 million, which would be essentially flat compared with the $92.4 million Inogen reported in the third quarter of 2025. On the bottom line, analysts expect a loss of about $0.11 per share, narrower than the prior-year quarter's loss. The company's own outlook aligns with this muted top-line view: management has said it expects third-quarter revenue to be "approximately in line" with the prior-year period, reflecting the continued U.S. sales channel mix shift and the timing of select international distributor inventory purchases.

In its most recent report, second-quarter 2026 revenue rose 3% year over year to $95.1 million, with adjusted gross margin improving 65 basis points to 45.6%. International sales climbed nearly 15% in that quarter, while U.S. sales and U.S. rentals declined. Investors will be watching whether those trends persist, and whether the company's full-year revenue guidance of $355 million to $361 million, which was lowered from a prior range of $366 million to $373 million, remains intact.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Inogen ahead of key earnings events, the tool offers a streamlined way to surface relevant opportunities across the healthcare and medical technology landscape.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautious. Inogen shares have struggled in 2026, with the stock down roughly 10% year to date through its second-quarter report, and the stock has drifted lower since that August release. The market appears to be weighing the company's progress toward breakeven against persistent headwinds in its U.S. direct-to-consumer and rental businesses. A key risk for the quarter is the timing of international distributor orders, which management has flagged as a factor that could dampen reported revenue even as underlying demand remains solid. How shares react will likely hinge on whether results confirm the expected sequential stabilization and whether management reiterates or adjusts its full-year outlook.

Forward Outlook and Key Factors to Monitor

Beyond the headline revenue and earnings figures, investors should focus on the trajectory of Inogen's three revenue categories: U.S. sales, international sales, and U.S. rentals. International performance has been the company's growth engine, and any signal that this momentum is sustained will be closely scrutinized.

Margin trends are another important factor. The company has been expanding adjusted gross margin through cost improvements, and progress toward adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) profitability is central to the investment thesis. For the full year 2026, management targets adjusted EBITDA of approximately $4.0 million, up from $2.7 million in 2025.

Finally, watch for updates on new product initiatives beyond the core POC business, including sleep therapy and airway clearance offerings, which management has positioned as part of a larger total addressable market. Commentary on the U.S. channel mix shift, distributor purchasing patterns, and any revision to full-year guidance will help shape the outlook for the remainder of the fiscal year.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations